These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27934627)

  • 1. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach.
    Snelder N; Ploeger BA; Luttringer O; Rigel DF; Webb RL; Feldman D; Fu F; Beil M; Jin L; Stanski DR; Danhof M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):356-367. PubMed ID: 27934627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
    Pelz A; Schaffert H; Diallo R; Hiepe F; Meisel A; Kohler S
    Eur J Immunol; 2018 Mar; 48(3):498-508. PubMed ID: 29205338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells.
    Sartawi Z; Ryan KB; Waeber C
    Eur J Pharmacol; 2020 Sep; 882():173262. PubMed ID: 32534075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
    Yagi Y; Nakamura Y; Kitahara K; Harada T; Kato K; Ninomiya T; Cao X; Ohara H; Izumi-Nakaseko H; Suzuki K; Ando K; Sugiyama A
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):39-47. PubMed ID: 25223691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
    Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
    Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
    Chun J; Giovannoni G; Hunter SF
    Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up.
    Ludwig R; Malla B; Höhrhan M; Infante-Duarte C; Anderhalten L
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.
    Colombo E; Bassani C; De Angelis A; Ruffini F; Ottoboni L; Comi G; Martino G; Farina C
    Front Immunol; 2020; 11():635. PubMed ID: 32322257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects.
    Biswal S; Polus F; Pal P; Veldandi UK; Marbury TC; Perry R; Legangneux E
    Int J Clin Pharmacol Ther; 2015 Oct; 53(10):855-65. PubMed ID: 26308174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of new ligands for targeting the S1P1 receptor.
    Schilson SS; Keul P; Shaikh RS; Schäfers M; Levkau B; Haufe G
    Bioorg Med Chem; 2015 Mar; 23(5):1011-26. PubMed ID: 25656338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
    Hale JJ; Lynch CL; Neway W; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Parent SA; Chrebet G; Bergstrom J; Card D; Ferrer M; Hodder P; Strulovici B; Rosen H; Mandala S
    J Med Chem; 2004 Dec; 47(27):6662-5. PubMed ID: 15615513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists.
    Hale JJ; Doherty G; Toth L; Mills SG; Hajdu R; Keohane CA; Rosenbach M; Milligan J; Shei GJ; Chrebet G; Bergstrom J; Card D; Forrest M; Sun SY; West S; Xie H; Nomura N; Rosen H; Mandala S
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3501-5. PubMed ID: 15177461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Effects of Long Term FTY720 Treatment on Endothelial versus Smooth Muscle Cell Signaling to S1P in Rat Mesenteric Arteries.
    Hamidi Shishavan M; Bidadkosh A; Yazdani S; Lambooy S; van den Born J; Buikema H; Henning RH; Deelman LE
    PLoS One; 2016; 11(9):e0162029. PubMed ID: 27583547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS; Kolontareva YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
    Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T
    PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
    Gergely P; Nuesslein-Hildesheim B; Guerini D; Brinkmann V; Traebert M; Bruns C; Pan S; Gray NS; Hinterding K; Cooke NG; Groenewegen A; Vitaliti A; Sing T; Luttringer O; Yang J; Gardin A; Wang N; Crumb WJ; Saltzman M; Rosenberg M; Wallström E
    Br J Pharmacol; 2012 Nov; 167(5):1035-47. PubMed ID: 22646698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siponimod in the treatment of multiple sclerosis.
    Goodman AD; Anadani N; Gerwitz L
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human.
    Pognan F; Mahl JA; Papoutsi M; Ledieu D; Raccuglia M; Theil D; Voytek SB; Devine PJ; Kubek-Luck K; Claudio N; Cordier A; Heier A; Kolly C; Hartmann A; Chibout SD; Bouchard P; Trendelenburg C
    Arch Toxicol; 2018 May; 92(5):1877-1891. PubMed ID: 29556671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S1PR1 (Sphingosine-1-Phosphate Receptor 1) Signaling Regulates Blood Flow and Pressure.
    Cantalupo A; Gargiulo A; Dautaj E; Liu C; Zhang Y; Hla T; Di Lorenzo A
    Hypertension; 2017 Aug; 70(2):426-434. PubMed ID: 28607130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
    Legangneux E; Gardin A; Johns D
    Br J Clin Pharmacol; 2013 Mar; 75(3):831-41. PubMed ID: 22845008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.